Karyopharm Therapeutics (KPTI) Non-Current Assets (2012 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Non-Current Assets came in at $5.3 million in Q4 2025, down 33.76% YoY from $8.0 million in Q4 2024, and down 18.75% on a QoQ basis from $6.5 million in Q3 2025.
Karyopharm Therapeutics (KPTI) Non-Current Assets (2012 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 14 years of Non-Current Assets data on file, last reported at $5.3 million in Q4 2025.
- Quarterly Non-Current Assets fell 33.76% year-over-year to $5.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $26.2 million (up 8.39% YoY) and the FY2025 annual result came in at $5.3 million, down 33.76% from the prior year.
- Non-Current Assets retreated to $5.3 million in Q4 2025, from $6.5 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $29.7 million in Q4 2021 to a low of $4.7 million in Q3 2024.
- A 5-year average of $10.0 million and a median of $7.4 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2021 — Non-Current Assets tumbled 78.99% — and 2025, when it surged 37.39%.
- Tracing KPTI's Non-Current Assets over 5 years: stood at $29.7 million in 2021, then sank by 73.03% to $8.0 million in 2022, then declined by 18.64% to $6.5 million in 2023, then increased by 22.08% to $8.0 million in 2024, then sank by 33.76% to $5.3 million in 2025.
- The last three Non-Current Assets figures came in at $5.3 million (Q4 2025), $6.5 million (Q3 2025), and $7.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.89 Bn | 131.04 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.05 Bn | 78.06 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.38 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 55.46 Bn | 50.32 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.30 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 18.06 Bn |
| 10 | Karyopharm Therapeutics | 56.00 Mn | 56.00 Mn | 32.35 Mn | 4.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.94 Mn |
| Dec 31, 2025 | 5.27 Mn |
| Sep 30, 2025 | 6.49 Mn |
| Jun 30, 2025 | 7.01 Mn |
| Mar 31, 2025 | 7.47 Mn |
| Dec 31, 2024 | 7.96 Mn |
| Sep 30, 2024 | 4.72 Mn |
| Jun 30, 2024 | 5.44 Mn |
| Mar 31, 2024 | 6.09 Mn |
| Dec 31, 2023 | 6.52 Mn |
| Sep 30, 2023 | 6.74 Mn |
| Jun 30, 2023 | 6.45 Mn |
| Mar 31, 2023 | 7.26 Mn |
| Dec 31, 2022 | 8.01 Mn |
| Sep 30, 2022 | 8.56 Mn |
| Jun 30, 2022 | 14.03 Mn |
| Mar 31, 2022 | 17.50 Mn |
| Dec 31, 2021 | 29.70 Mn |
| Sep 30, 2021 | 12.52 Mn |
| Jun 30, 2021 | 13.07 Mn |